| 弥漫大B细胞淋巴瘤细胞耐药的研究进展 |
| |
| 引用本文： | 许晓强. 弥漫大B细胞淋巴瘤细胞耐药的研究进展[J]. 白血病．淋巴瘤, 2011, 20(2): 126-128 |
| |
| 作者姓名： | 许晓强 |
| |
| 作者单位： | 山西省汾阳医院血液科,032200 |
| |
| 摘 要： | 弥漫大B细胞淋巴瘤（DLBCL） 化疗耐药的主要原因是细胞耐药。研究表明DLBCL细胞耐药与耐药基因及其耐药相关蛋白、细胞因子、黏附分子有关，并在造血微环境中通过信号转导介导细胞耐药。
|
| 关 键 词： | 淋巴瘤 大细胞 弥漫型 多药耐药相关蛋白质类 信号传导 |
Advances of the drug resistance of the diffuse large B-cell lymphoma |
| |
| XU Xiao-qiang. Advances of the drug resistance of the diffuse large B-cell lymphoma[J]. Journal of Leukemia & Lymphoma, 2011, 20(2): 126-128 |
| |
| Authors: | XU Xiao-qiang |
| |
| Affiliation: | XU Xiao-qiang＊, ZHA NG Qiao-hua, BA I Lin-hai. ＊Department of Hematology, Shanxi Provincial Fenyang Hospital, Fenyang 032200, China |
| |
| Abstract: | The chemoresistance of diffuse large B-cell lymphoma （DLBCL） is mainly due to drug resistance. Studies have shown that DLBCL resistance is related to the resistance gene and its resistance- related protein, cytokines, adhesion molecules, which led to drug resistance through signal transduction in the hematopoietic mieroenvironment. |
| |
| Keywords: | Lymphoma, large-cell, diffuse Multidrug resisbance-associated proteins Signaltransduction |
| 本文献已被 维普 万方数据 等数据库收录！ |
| 点击此处可从《白血病．淋巴瘤》浏览原始摘要信息 |
|
点击此处可从《白血病．淋巴瘤》下载免费的PDF全文 |
